Hormonal
Prolonged sleep restriction (4 hours/night for 5 nights) increases cardiovascular disease risk by augmenting proinflammatory responses, specifically through elevated IL-17 and C-reactive protein (CRP) levels, which persist even after recovery sleep.
If you consistently restrict your sleep to around 4 hours per night for several days, your body enters a proinflammatory state characterized by high levels of IL-17 and CRP. This state persists even if you sleep normally for two days afterward. Since these markers are linked to cardiovascular disease risk, prioritizing consistent, sufficient sleep duration is critical for long-term heart health, rather than relying on weekend recovery alone.
5 nights of sleep restriction increased lymphocyte activation and the production of proinflammatory cytokines including IL-1b IL-6 and IL-17; they remained elevated after 2 nights of recovery sleep, accompanied by increased heart rate and serum CRP, 2 important risk factors for cardiovascular diseases. Therefore, long-term sleep restriction may lead to persistent changes in the immune system and the increased production of IL-17 together with CRP may increase the risk of developing cardiovascular diseases.
Why this rating
Randomized controlled laboratory trial with a control group, measuring multiple biological markers, though the sample size is small (n=13 experimental).
Source
Sleep Restriction Increases the Risk of Developing Cardiovascular Diseases by Augmenting Proinflammatory Responses through IL-17 and CRP
Wessel van Leeuwen et al. · PLoS ONE · 2009
DOI 10.1371/journal.pone.0004589
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →